DXRX Lab Talk: NRG1 fusions testing
Our latest Lab Talk with Dr. Kurt Schalper explores pathogenic gene fusions as oncogenic drivers and actionable biomarkers in precision oncology, focusing on NRG1 fusions.
Date: September 16th 2024
Time: 3pm ET
Agenda
- Overview of precision oncology
- Pathogenic gene fusions as oncogenic drivers
- NRG1 fusions: clinical utility in cancer
- Testing for NRG1 fusions
- Q&A
Can't make the live session? Register and we'll send you the recording!
Speaker name: Kurt A. Schalper, M.D./Ph.D. Associate Professor of Pathology and Medicine (Medical Oncology), Yale School of Medicine. Director Translational Immuno-oncology Laboratory, Yale Cancer Center
Dr. Schalper trained as cell/molecular biologist and surgical pathologist. His professional experience includes clinical molecular diagnostics and development of cancer biomarkers. His laboratory focuses on understanding the interaction between molecular oncogenic pathways and immune evasion, and deciphering the structural/functional determinants of the tumor microenvironment in solid tumors. Dr. Schalper is also the director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center where he leads the standardized analysis of biomarkers in clinical trials using advanced cell/tissue analysis platforms.